Headshot of Jared Gollob
Area of Focus
Publish Date
November 13, 2023
Jared Gollob, MD, Chief Medical Officer

Nature Medicine Publication: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

We’re thrilled to share the positive results from the Phase 1 trial of our first-in-class IRAK4 degrader, KT-474, have been published in Nature Medicine! This is the first published clinical trial using a heterobifunctional degrader and highlights the transformative potential of IRAK4 degradation in TLR/IL-1R-driven immunological diseases.